Genfit S.A. (GNFT)

Market Cap	210.44M
Revenue (ttm)	86.23M
Net Income (ttm)	23.86M
Shares Out	49.78M
EPS (ttm)	0.47
PE Ratio	8.82
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,168
Open	4.330
Previous Close	4.480
Day's Range	4.180 - 4.330
52-Week Range	3.080 - 6.420
Beta	1.12
Analysts	Strong Buy
Price Target	13.00 (+209.52%)
Earnings Date	Sep 19, 2024

About GNFT

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 27, 2019
• Employees: 159
• Stock Exchange: NASDAQ
• Ticker Symbol: GNFT
• Website: https://www.genfit.com

Financial Performance

In 2023, Genfit's revenue was 34.48 million, an increase of 31.38% compared to the previous year's 26.25 million. Losses were -28.89 million, 21.8% more than in 2022.

Financial numbers in EUR

Analyst Forecast

According to one analyst, the rating for GNFT stock is "Strong Buy" and the 12-month stock price forecast is $13.0.

Price Target

$13.0

(209.52% upside)

Analyst Consensus: Strong Buy